FDA Study Halted After Jane Goodall Objects

The primatologist had written to the agency that the trial, which involved observing the effects of nicotine addiction in squirrel monkeys, was “cruel and unnecessary.”

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, BORIS23The US Food and Drug Administration (FDA) has paused a study of nicotine addiction in squirrel monkeys that primatologist Jane Goodall objected to. She wrote a letter—in which she called the research “horrific”—to FDA Commissioner Scott Gottlieb. Although Gottlieb communicated with Goodall, an FDA spokesman tells The Scientist that the agency's decision to stop the study was independent of her plea. The letter from Goodall, an outspoken animal rights advocate, was posted on the website of the White Coat Waste (WCW) Project, an organization that seeks to stop animal research funded by US taxpayers, earlier this month (September 7).

According to the Washington Post, Gottlieb responded to Goodall on Monday (September 25), saying that he would temporarily suspend the three-year-old study, which FDA researchers are conducting at the agency’s National Center for Toxicological Research in Arkansas. The FDA commissioner reportedly assured Goodall that he made the decision “after learning of concerns related to the study you referenced,” and said that he was dispatching primate experts to the Arkansas facility “to evaluate the safety and well-being of the monkeys and to understand whether there are additional precautions needed.”

In her letter, Goodall took issue with the fact that juvenile monkeys were being implanted with devices that delivered nicotine directly into their systems and then taught to press a lever that dosed them with the drug. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies